Jupiter, FL – [January 16, 2024] – After milestone review by the NIH’s National Cancer Institute (NCI), Myosin Therapeutics is excited to announce that it has successfully transitioned to the second phase of funding through the NCI Small Business Technology Transfer (STTR) Fast Track program. Myosin Therapeutics will be awarded an additional $2.5 million. The Mayo Clinic, a key partner in this program, will continue its collaborative efforts with Myosin Therapeutics to advance MT-125 toward clinical trials.
The NCI STTR program supports small businesses in developing and commercializing novel cancer-related technologies. Myosin Therapeutics and the Mayo Clinic have been actively participating in this multi-part program to develop MT-125 as a promising new treatment for glioblastoma. This second round of funding will build on the success of the initial research phase and accelerate the comprehensive development plan for MT-125.
In the first part of the program, Myosin Therapeutics, in partnership with Steven Rosenfeld, MD, PhD of Mayo Clinic, achieved several key objectives: confirmed preclinical efficacy of MT-125 using a clinically viable route of administration, conducted in vitro studies of synergy between MT-125 and existing FDA-approved treatments, and performed in vitro safety profiling. Additionally, the team carried out pre-formulation studies and a demo batch scale-up of MT-125, establishing a solid foundation for further development.
With the support of this next round of funding, Myosin Therapeutics and the Mayo Clinic will conduct further in vivo efficacy testing, focusing on the most promising combination therapies identified in the initial research. The team will also perform a non-GLP dosing range finding toxicology study, GLP synthesis, and formulation development to optimize MT-125 for clinical use. Upon completion of these activities, the company will be in an excellent position to submit an Investigational New Drug (IND) application to the FDA, a crucial step toward initiating clinical trials.
“Our transition to the second phase of funding through the NCI STTR Fast Track program is a testament to the potential of MT-125 as an innovative treatment for glioblastoma,” said Dr. Courtney Miller, CEO and co-founder of Myosin Therapeutics. “We are incredibly grateful for the NCI’s continued support and to have Mayo Clinic as a strong partner in this venture. Together, we are well-equipped to advance MT-125 through this next stage of development and build a comprehensive data package for IND submission.”
About Myosin Therapeutics
Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of the Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for oncology and central nervous system indications with a platform for targeting molecular nanomotor proteins. Myosin’s lead programs for glioblastoma and stimulant use disorder target non-myosin motor II proteins.
About Mayo Clinic
Mayo Clinic is a nonprofit American academic medical center focused on integrated clinical practice, education, and research. With a team of expert clinicians, researchers, and scientists, Mayo Clinic is at the forefront of patient care and medical advancements. The institution’s dedication to improving patient outcomes, particularly in oncology, makes it a key collaborator in advancing innovative treatments for diseases like glioblastoma.
For more information, email contact@myosintherapeutics.com
